Results from the Phase IIb MYR204 study demonstrated that Gilead’s combination of bulevirtide with pegylated interferon ...
People may someday have a surprisingly familiar tool to prevent viral infections: one of the antibiotics found in a common ...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing ...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that ...
Half of the patients had prior interferon experience." In patients who received 2 ... HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression ...
A new study reveals that aging human pancreatic beta cells display features of senescence while maintaining elevated levels ...
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platformLAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- ...
2d
Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.
With Phase III trial results looming in the second quarter of 2024, Annexon Biosciences aims to transform treatment for ...
This response, termed the “interferon response” normally acts to indicate a viral infection to immune cells, recruiting their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback